Discussion
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for multiple…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
Multiple myeloma patients taking the immunomodulatory drug thalidomide may develop a potentially life-threatening dermatologic disorder called toxic epidermal necrolysis (TEN), according to a recent case…
Discussion
Combining three well-known oral drugs shows potential for heavily pretreated multiple myeloma patients who have grown resistant to therapy with one of the included drugs, according…
Discussion
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard two-drug regimen of Revlimid (lenalidomide) and dexamethasone significantly improves health-related quality of life in relapsed multiple…
Discussion
The anti-CD38 agent Darzalex (daratumumab) will be investigated in a Phase 3 clinical trial in combination with Kyprolis (carfilzomib) and Decadron (dexamethasone) in relapsed/refractory multiple…
Discussion
The U.S. Food and Drug Administration (FDA) has verbally notified BioInvent International that it’s placing a full clinical hold on the company’s Phase 2 trial evaluating…
